Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilofotase alfa for prevention of renal damage after cardiac surgery
NL-OMON59752Phase 2Completed
- Sponsor
- AM-Pharma
- Start
- Feb 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of ilofotase alfa in acute kidney failure (AKF), sponsored by AM-Pharma. Primary endpoint: Peak postoperative serum creatinine ratio. Started Feb 2024; status: completed.
02
Drugs
ilofotase alfa
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on NL-OMON59752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59752.